Hikma Pharmaceuticals Share News (HIK)
HIK Share
HIK Share
HIK Share
HIK Share
HIK
HIK Share
HIK Level 2
HIK Live
HIK Broker
HIK Directors
HIK Financial
HIK
HIK Short
HIK
Last checked at -
Aggreko: RBC Capital reduces target price from 1850p to 1680p, while its neutral rating remains unchanged. Aviva: JP Morgan raises target price from 393p to 436p and retains an overweight rating. BHP Billiton: Canaccord Genuity takes target price from 1950p to 2050p maintaining a hold recommendati
Read moreInternet shopping group N Brown was a high riser today after Credit Suisse raised its rating for the stock from 'neutral' to 'outperform' and lifted its target price from 455p to 620p. N Brown, whose brands include Simply Be, Jacamo and Figleaves, has seen its stock surge by around 50% so far this
Read moreMarkets were sharply lower on Wednesday morning as risk appetite was scaled back ahead of this evening's release of the minutes of the latest Federal Reserve policy meeting. The FTSE 100 was trading as low as 6,400 today in London today; the last time it closed below this level was on July 5th when
Read more
* Sees 2013 revenue growth of 20 pct * First-half profit up 93 pct * First-half revenue up 20 pct By Abhirup Roy Aug 21 (Reuters) - Hikma Pharmaceuticals raised its full-year revenue forecast for the third time in four months, riding on strong sales of generic antibiotic d
Read moreThe FTSE 100 fell into the red on Wednesday morning, hitting a fresh six-week low as investors nervously awaited the minutes of the latest Federal Reserve meeting. The index dropped 0.5% to around the 6,420 mark early on. The last time the London benchmark closed lower was on July 5th when it finis
Read moreMarkets are expected to open lower on Wednesday morning as traders nervously await the minutes of the latest Federal Reserve meeting. City sources predict the FTSE 100 will open down 12 points after hitting a six-week low of 6,453.46 yesterday. Market sentiment has been a little fragile ahead of
Read moreHikma Pharmaceuticals said it had made a strong start to the first half of its financial year, with all of its businesses performing well, as it raised its guidance to around 20 per cent revenue growth for the year. The multinational pharmaceutical firm said revenue increased by 19.9% to $638.3m in
Read moreAug 21 (Reuters) - Hikma Pharmaceuticals said it expected full-year revenue to rise 20 percent as strong sales of its generic antibiotic doxycycline in the United States continue and reported a 93 percent jump in first-half profit. The company, which makes and sells branded and generic drug
Read moreAquarius Platinum: Deutsche Bank lowers target price from 63p to 60p keeping a buy recommendation. Ashmore Group: HSBC ups target price from 400p to 435p, while keeping overweight rating. ASOS: UBS raises target price from 4600p to 6000p staying with its buy recommendation. Aviva: Bank of America
Read more* Sun Pharmaceutical Industries Ltd rises 1.1 percent to near a record high and a second day of gains, after a competitor raised revenue guidance citing strong sale of a generic antibiotic also sold by Sun Pharma. * Hikma Pharmaceuticals Plc on Monday raised its full-year revenue forecast for the
Read moreStocks registered a solid gain on Monday on the back of an advance in the banking sector. That came on the heels of what some economists termed a solid jobs report last Friday Stateside and upwards revisions to growth forecasts for the UK. Leading gains were shares of Royal Bank of Scotland, as Ch
Read morePharmaceutical group Hikma Pharmaceuticals topped the leaderboard after saying it expects revenue to grow by 17 per cent in 2013 compared to its previous guidance of 13 per cent. Bovis Homes Group gained after announcing its reservations in the first half were ahead of its expectations amid signs o
Read more* Expects full-year total revenue to rise 17 percent * Sees full-year generics business revenue of $200 mln * Shares up as much as 9 pct (Adds analysts' comments, details; updates share movement) July 8 (Reuters) - Hikma Pharmaceuticals Plc raised its full-year revenue forecas
Read moreAnglo American: Exane reduces target price from 1700p to 1400p and reiterates its underperform rating. Anite Group: Investec raises target price from 135p to 155p and upgrades from hold to buy. Ashmore Group: RBC Capital Markets takes target price from 440p to 375p and keeps its neutral rating. B
Read moreLondon's leading shares started the week on strong footing after Friday's better than expected US nonfarm payrolls number and as focus turns to European Central Bank (ECB) President Mario Draghi's speech to European Parliament. Friday's widely watched report from the Labor Department showed US empl
Read more
Last checked at